Noduläres Lymphozyten-prädominantes Hodgkin-Lymphom im Kindes-und Jugendalter: Therapieempfehlungen der GPOH-HD Studiengruppe 2002 trial about 22 % of the nLPHL patients were diagnosed in stage > IIA compared to about 61 % of patients with cHL. Thus, nLPHL possibly has a lower tendency to spread systemically. The most striking difference between cHL and nLPHL is the significantly increased risk of transformation from nLPHL into aggressive B cell lymphoma. Cumulative transformation rates increase by time, approaching 15 % after 15 years from diagnosis without an apparent plateau. The transformation risk tends to be higher in nLPHL patients with clinical stage III or IV at presentation [2, 6] . These reports may indicate that nLPHL and cHL are biologically distinct entities, probably justifying different treatment approaches.
Introduction

▼
Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is a rare CD20 positive 'subtype' of Hodgkin lymphoma that has recently been recognized by the WHO as a distinct disease entity [15] . Typically, patients present with peripheral, early stage disease mainly in clinical stage IA or IIA with a high preponderance of male subjects. In contrast to classical Hodgkin lymphoma (cHL), mediastinal lymphoma manifestation is exceptional and if present, mostly comprises more advanced stage disease. Advanced stages (clinical stages III and IV) are prevailing only in approximately 20 % of the patients [26] . In the GPOH-HD ▼ Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is a very rare disease in childhood and adolescence. In Germany, about 15 newly diagnosed patients present with this disease annually; this number comprises less than 10 % of all pediatric Hodgkin lymphoma cases. Since the EuroNet-PHL-LP1 trial for early stage nLPHL patients stopped recruiting in Germany in October 2014, the GPOH-HD writing committee reviewed the literature and decided to deliver treatment recommendations for childhood and adolescent nLPHL patients. These guidelines shall be applicable to young nLPHL patients in European countries that will no longer be able to participate in nLPHL trials for young patients. Therefore, the EuroNet-PHL-nLPHL-registry will be installed to provide quality assured central review of staging and response assessment for registered patients by the Central Review Board of EuroNet-PHL in Halle/Leipzig, Germany. ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■
In adult nLPHL patients, the 5-year overall survival is about 95 % and appears to be more favorable for early stage nLPHL patients compared to patients with cHL when using the same intensive treatment approaches [26] . Especially in older adult patients, prevention of relapse and second line treatment is important. Therefore, guidelines, like the German S3-guideline on diagnostics and treatment for adult Hodgkin lymphoma patients, recommend involved field radiotherapy with 30 Gy for stage IA nLPHL patients and suggest treatment according to cHL for all other stages [3, 9, 19] . For children and adolescents with nLPHL, low intensity treatment regimens may be more appropriate [33] since in this age group treatment strategies focus on the prevention of late effects for a disease with excellent cure rates. Thus, in young nLPHL patients low intensity first line treatment might be a valuable trade-off between an increased relapse rate vs. increased long-term side effects. The ultimate goals are to keep the excellent overall survival rates and to induce long-term remissions in the majority of patients. However, the rare incidence of the disease does not allow for randomized trials. This fact is limiting the number of prospective trials in this rare entity; most evidence has arisen from retrospective analyses. For quality assurance, a systematic follow-up of this patient population is strongly required to gain ample knowledge on the course of the disease and the response to distinct treatment approaches. However, currently the regulatory authorities limit the conduct of so called 'registry trials', since the inclusion of treatment recommendations into a registry protocol will be considered as a phase IV trial according to drug law. In addition, in rare diseases the total duration of such trials would be too long to recruit a meaningful sample of patients. Furthermore rapid analyses for evolving interventions would be hampered, e. g. in very small subgroups of patients. To overcome these limitations, the Pediatric Hodgkin Network of the GPOH-HD study centre in Halle/ Leipzig offers central review of staging and response assessment, i. e., expert/second medical opinion, for all patients registered into the nLPHL registry irrespective of the treatment, which will be chosen by the treating physicians [23] .
Histopathology assessment -expert pathology review is mandatory ▼ The role of FDG-PET in nLPHL ▼ Data on the value of PET in diagnosis and response assessment of nLPHL is very limited. A retrospective report on 35 nLPHL patients describes the role of using FDG-PET for staging in nLPHL patients [13] . In this study, the sensitivity of pre-therapeutic PET-CT was 100 %. In a per-site analysis, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of pre-therapeutic PET-CT were 100, 99, 97, 100 and 99 %. FDG-PET had led to changes in initial or relapse stage assessment in 12/35 patients (34 %). Finally, the investigators found a surprisingly high prevalence of skeletal involvement, which might be overestimated due to the small cohort size. These data point to the value of FDG-PET for staging in nLPHL as it is practiced in the Euro-Net-PHL group since 2009 when the the EuroNet-PHL-LP-1 trial started [22] . In this trial, FDG-PET is used for the decision on involvement in case of questionable lymph nodes (i. e., in lymph nodes with diameters between 1 and 2 cm) or questionable extranodal involvement. Correct staging is of utmost importance especially when low-intensity treatment for early stage disease or a surgery alone approach for stage node is intended. Therefore, the initial staging has to include PET-CT, PET-MRI or PET with concomitant CT/MRI followed by an expert panel review of the images.
Risk factors ▼
According to current data, risk factors include histopathology variants, sex, stage, age and hemoglobin levels. The German Hodgkin Study group (GHSG) [16] evaluated the prognostic score including histopathologic pattern (0 = typical nLPHL, 1 = variant growth pattern according to Fan et al. [12] ), albumin (0 = albumin ≥ 4 g/dL, 1 = albumin < 4 g/dL), and gender (0 = female, 2 = male). Patients with a score of 3 or higher had a decreased 5-year progression free survival (68.7 %) and overall survival (88.3 %) compared to patients without risk factors (PFS 95.2 % and OS 98.7 %). In a retrospective analysis on a cohort of 394 nLPHL patients the GHSG showed that advanced stage (i. e., IIB with mediastinal bulk or extranaodal disease or > IIB), hemoglobin levels less than 10.5 g/dl and age above 45 years were negative prognostic factors for overall survival [26] . These findings are strengthening the point of view that young people require different and most probably less intensive treatment approaches. Sohani et al. found in 11 nLPHL patients with atypical T cell patterns an increased relapse rate compared to that of 24 patients with normal nLPHL pattern (71.4 vs. 13.6 %, P = 0.008). However, the overall survival does not seem to be inferior [35] .
In conclusion, in nLPHL patients the exact histopathology description should be prospectively documented and correlated with disease stage and outcome in a dedicated nLPHL registry. Since the actually published scores are not yet validated, it may be currently too early to delineate treatment decision along the described risk factors.
Treatment reviews ▼
An overview of data on treatment modalities with respect to different age groups is depicted in
• ▶ Table 1 ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■ Table 2 Treatment and outcome in childhood and adolescent nLPHL. 
Treatment for patients with stage IA Treatment with radiotherapy
In a small retrospective analysis 20 out of 36 stage IA or IIA patients with lymphocyte-predominant Hodgkin lymphoma, presented with stage IA and received only supradiaphragmatic radiotherapy with 40 Gy. These patients showed excellent 5-year relapse free survival (95 %) and overall survival (100 %) [31] . These results were confirmed by other retrospective analyses [7, 27, 37 ] ( • ▶ Table 1 ), suggesting that radiotherapy alone might be a favorable approach for adult stage IA nLPHL patients to achieve high cure rates with the first line of treatment. However, the cumulative incidence of late complications increases with longer follow-up periods [18] and therefore the 10-, 15-and 20-year PFS and OS rates are substantially declining [38] . Thus, radiotherapy should be avoided as much as possible in children and young people with limited stage nLPHL, since the prevention of late effects in young people seems more important than the prevention of first relapses as long as the overall survival rates are not impaired.
Treatment with Rituximab
A low intensity treatment approach for stage IA nLPHL patients has been used in a phase II trial using rituximab. Eichenauer et al. included 28 newly diagnosed nLPHL patients with stage IA [10] to receive 4 weekly standard doses of rituximab. Treatment related toxicities were documented to be of grade II or lower. The overall survival was excellent (100 %); however, the 4-year PFS was only 77.1 %. In conclusion, the efficacy of rituximab monotherapy is moderate and might be acceptable, but the limitation of this approach is that long-term safety data of rituximab in children and adolescents are missing.
Watchful waiting: No treatment after complete resection
An alternative approach might be a watch-and-wait strategy after complete resection. Some retrospective analyses in children, but not in adults, report on such strategies. The French Pediatric Hodgkin study group reported retrospectively on a surgery alone strategy in 13 LPHL patients [28] ( • ▶ Table 2): In 2 patients with stage IIIA and 2 patients with stage IA no complete resection was achieved; subsequently, these patients relapsed. In 9 stage IA patients complete resection was achieved and only 3 of 9 relapsed again, 2 in stage IA and one in stage IIA, indicating that surgery alone might be a useful treatment option in stage IA patients with complete resection. Similar results were reported in a retrospective analysis on a surgery alone approach by the EuroNet-PHL Group in 58 patients [24] . 54 patients were in stage IA, 2 in IIA and 2 in IIIA. The overall survival was 100 % with a median follow-up of 43 months. In 51 patients complete resection was achieved and the 50-months progression-free survival of this group was 67 %, while all 7 patients with incomplete resection relapsed. All relapsing stage IA patients had recurrences in early stages again, i. e., in stage IA and IIA. Transformations into aggressive B cell lymphoma did not occur in those patients. Early results of a prospective trial with a surgery alone strategy reporting on 52 patients with complete resection and with a median follow-up of 48 months revealed 9 relapsing patients, 8
in stage IA and one in stage IIA. The 2-year EFS and OS are 80.3 and 100 %, respectively [5] . However, the 2 year follow-up time might be too short for a meaningful analysis. Taken together, in nLPHL stage IA patients with complete resection at biopsy or at re-surgery a watch-and-wait strategy might be feasible. Probably 2 thirds of the patients will achieve longterm remission using a treatment option without any risk for long term sequelae. However, patients should be informed that most evidence for this approach has been obtained by retrospective analyses.
Treatment for patients with stage IIA and IA without complete resection Treatment with intensive chemoradiotherapy
There are several reports in adult patients showing excellent cure rates with rather intensive chemotherapy and/or radiotherapy regimens ( • ▶ Table 1 ). Chen et al. reported on a 10-year OS rate of 94-97 % in stage I and II patients mainly treated with radiotherapy alone. However 8/113 patients died of secondary cancer or cardiac disease and 5 of 6 fatal cancers developed in prior radiotherapy fields [7] . In addition, 9 patients developed secondary cancer and are alive. In a retrospective analysis Wirth et al. evaluated a radiotherapy alone approach (median dose 36 Gy) in 202 stage I and II patients. The OS and PFS at 15 years were rather poor with 83 and 82 %. At 15 years the cumulative incidence of secondary malignancies (SMs) was 11 and 4 % of the patients developed in-field SMs [38] . The GHSG reported on 394 nLPHL patients treated between 1988 and 2002 and compared these results to 7 904 cHL patients treated in the same trials. The overall survival was 96 % for nLPHL patients and 92 % for cHL patients. The total relapse rate in early favorable nLPHL patients was 5.7 % and was therefore not different to that of cHL patients (8.8 %), 2.4 % of them died and 2.8 % developed secondary cancer. All patients had been treated with chemo-radiotherapy regimens [26] . A report from British Columbia showed that in adult nLPHL patients presenting in stage IA/B or IIA the 10-year OS rate improved by using ABVD-based chemotherapy with or without radiotherapy vs. radiotherapy alone (93 vs. 84 %) [30] . The UK Children`s Cancer Group reported on 42 children with nLPHL of whom 35 presented in stage I and II [14] . At a median follow-up of 8.9 years only one of 42 patients had died. Patients had been treated with either radiotherapy alone (offered to stage IA patients only) or ChlVPP (chlorambucil, vincristine, procarbazine and prednisone) chemotherapy (offered to all stages). The North American Children's Oncology Group (COG) reported on 52/82 patients receiving chemotherapy alone (COPP/ABV for early stages) [4] . In 29/82 patients who did not achieve complete remission after chemotherapy, radiotherapy (21 Gy) was administered. 66/82 patients presented in early stages. For the total cohort the 5-year PFS was 97 % and the OS was 100 %. In conclusion, children and adolescents with early stage nLPHL, seem to have an excellent prognosis with intensive treatment. Therefore, it is an important question whether low intensity chemotherapy is safe enough to reduce or prevent long-term sequelae in early stage nNLPHL patients with incomplete resection. ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■ 58 % in patients receiving 4 additional rituximab doses over a period of 2 years). Of the 23 relapsing patients 9 had transformations into aggressive B-cell lymphoma. In 4 of the 9 patients with transformations multiple relapses occurred before the transforming event. Thus, the role of rituximab in these transforming events is not clear.
Treatment with Rituximab monotherapy
Treatment with low-intensity chemotherapy
The French and the UK group piloted a low intensity chemotherapy regimen using 3 cycles of CVP (cyclophosphamide 500 mg/ m² on day 1; vinblastine 6 mg/m² on day 1 and 8 and prednisone 40 mg/m² on days [1] [2] [3] [4] [5] [6] [7] [8] . In a retrospective analysis they report on 55 children [34] . 36/45 patients who received CVP for first line treatment achieved complete remission (CR) or complete remission unconfirmed (CRu) and 9 patients were in partial remission (PR). 10 patients received CVP for relapse after a surgery alone approach. The 40-months freedom from treatment failure (FFTF) rate and OS rate was 75.4 and 100 %, respectively. Thus, the majority of good responders achieved long-term remission using low intensity treatment in first line. The relapsing patients could be salvaged, achieving CR with a more intensive chemotherapy. Therefore, the CVP regimen might be offered to early stage nLPHL patients ineligible for a watch-and-wait strategy after surgery.
Treatment for patients without CRu after low intensity chemotherapy (CVP) or relapse after CVP
For the few patients who either do not respond well to CVP chemotherapy or present with relapse after CVP, the treatment approach of the GPOH-HD-95 trial might be suitable. The GPOH-HD study group treated 78 patients with early stage LPHL within the GPOH-HD95 trial [8] . 69 patients received OEPA (boys) or OPPA (girls) chemotherapy and 9 patients with complete resection did not receive any further treatment. 49/69 patients achieved CR according to the definition described by Dörffel et al. [8] . Only 2/49 patients have relapsed to date (W. Dörffel et al., unpublished data). In 20 patients without CR, modified involved field radiotherapy with 20 Gy was applied. While application of radiotherapy is the established standard, future investigations should focus on the role of rituximab in combination with chemotherapy to determine whether such an approach could safely replace radiotherapy.
Treatment for patients with advanced stage nLPHL Standard treatment options
In adult patients with advanced stage nLPHL or cHL treated with ABVD-based chemotherapy Xing et al. performed a matched pair analysis [39] . They found comparable, but rather low FFTF rates (75 vs. 73 % at 10 years) for nLPHL and cHL. Splenic involvement was associated with higher relapse rates in nLPHL and an increased cumulative incidence of aggressive NHL, suggesting that these patients should receive more intensive treatment in first line. In a report of the GHSG 63/394 nLPHL patients presented with early unfavorable disease (stages I and II with risk factors) and 82/394 patients with advanced stage disease (stage IIB or higher with risk factors) [26] . The death rate for early unfavorable and advanced stage nLPHL patients (6.3 or 9.8 %), rate of secondary malignancies (1.6 or 2.4 %) and 50 months FFTF rate (87 or 77 %) of nLPHL patients were similar to those of the cHL patients treated within the same protocols.
Data on treatment results in children with advanced stage nLPHL are very rare due to the very low incidence of these disease stages [14, 29] . Traditionally, such patients have been treated according to cHL protocols. To date, there are no systematic data whether a PET-based decision for the omission of radiotherapy like in patients with cHL can be extrapolated for the treatment of nLPHL patients. Administration of radiotherapy to all advanced stage nLPHL using the GPOH-HD-2002 based OEPA-COPDAC strategy might be the safest strategy [25] .
Alternative treatment options
Since in patients with intermediate or advanced stage nLPHL the risk of transformation into NHL might be increased [2, 6] , NHLbased treatment regimens combined with targeted treatment could be an alternative option. However, evidence-based data are very limited. Fanale et al. reported on 15 nLPHL patients of whom 11/15 patients presented in advanced stages and were treated with R-CHOP (rituximab in combination with CHOP). With a median follow-up time of 42 months no relapses or NHL-transformation occurred [11] . However, the retrospective analysis and the small number of patients limit the value of this report.
Treatment options in relapsing patients
So far, there is only one report on 26 relapsing nLPHL patients treated with high-dose chemotherapy followed by autologous stem cell transplantation [21] . The 5-year overall and event-free survival was 75 and 69 % using various high-dose chemotherapy regimens (R-BEAM, CBV, BEAM and others) followed by autologous stem cell transplantation. Advani et al. 
Concluding recommendations ▼
The concluding recommendations are limited by small numbers of patients and mainly retrospective analyses. Following the philosophy of low-intensity first line treatment for early stage nLPHL patients as long as the overall survival is not reduced and long-term remission is induced in the majority of patients, the GPOH-HD study writing committee suggests,: ▶ Correct staging and response assessment seems essential especially when using low-dose strategies. Therefore, the EuroNet-PHL reference center offers central review for patients registered in the upcoming EuroNet-PHL-nLPHL-registry. ▶ For stage IA patients with complete resection: watch-and-wait strategy, although about 30 % of these patients will relapse. However, 70 % will not be treated with chemotherapy or radiotherapy. ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■ Mauz-Körholz et al. [25] ) or relapse, the GPOH-HD-95 strategy using OEPA chemotherapy and modified involved field radiotherapy (in patients not achieving CR after 2 cycles of OEPA) might offer an excellent second line treatment. ▶ Patients in intermediate or advanced stage disease might be treated similar to the most recent standard cHL treatment. However, since there is no data on early response PET-based omission of radiotherapy like in cHL patients, these patients should be treated with combined modality treatment options. Alternatively, considering the increased risk of NHL transformation R-CHOP might be offered although data supporting this option are very limited. ▶ Relapsing patients might be treated similar to relapsing cHL patients with or without using rituximab as a targeted treatment.
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